About Alacris Theranostics
Alacris Theranostics positions itself as a systems medicine company, delivering integrated next-generation sequencing (NGS) services and bioinformatics solutions designed to translate multi-modal omics data into actionable insights for researchers, pharmaceutical partners and healthcare professionals.
Based in Germany, the company's core offering spans the full omics workflow, from NGS data generation through to computational interpretation. Its bioinformatics capability is presented as central to the value proposition, enabling clients to move from raw sequencing output to clinically and scientifically meaningful results without switching vendors or platforms. The company also offers immune repertoire analysis alongside its broader genomics portfolio.
A distinctive element of Alacris Theranostics' research and development work is the ModCell digital twin concept, a computational modelling approach aimed at supporting personalised medicine applications. The Alacris-CMTA platform is referenced within this context, reflecting an ambition to connect molecular profiling with precision oncology decision-making.
The company's stated mission is to make comprehensive NGS services accessible across the research and pharma sectors, with a declared focus on advancing precision medicine and improving patient outcomes. Its approach emphasises customisation, on the basis that each project and each patient presents distinct challenges that standardised pipelines may not adequately address. Quality management, equality and diversity commitments, and an environmental policy statement are all cited on its public-facing communications, indicating structured internal governance.
Further information is available at alacris.de.
